Dynamic prediction of advanced colorectal neoplasia in inflammatory bowel disease.
Crohn’s disease
prognosis
screening
ulcerative colitis
Journal
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
ISSN: 1542-7714
Titre abrégé: Clin Gastroenterol Hepatol
Pays: United States
ID NLM: 101160775
Informations de publication
Date de publication:
29 Feb 2024
29 Feb 2024
Historique:
received:
11
10
2023
revised:
31
01
2024
accepted:
03
02
2024
medline:
3
3
2024
pubmed:
3
3
2024
entrez:
2
3
2024
Statut:
aheadofprint
Résumé
Colonoscopic surveillance is recommended in patients with colonic inflammatory bowel disease (IBD) given their increased risk of colorectal cancer (CRC). We aimed to develop and validate a dynamic prediction model for the occurrence of advanced colorectal neoplasia (aCRN, including high-grade dysplasia and CRC) in IBD. We pooled data from six existing cohort studies from Canada, the Netherlands, the UK, and the USA. Patients with IBD and an indication for CRC surveillance were included if they underwent at least one follow-up procedure. Exclusion criteria included prior aCRN, prior colectomy, or an unclear indication for surveillance. Predictor variables were selected based on literature. A dynamic prediction model was developed using a landmarking approach based on Cox proportional hazard modelling. Model performance was assessed with Harrell's concordance-statistic (discrimination) and by calibration curves. Generalizability across surveillance cohorts was evaluated by internal-external cross-validation. The surveillance cohorts comprised 3,731 patients, enrolled and followed-up in the time period 1973-2021, with a median follow-up of 5.7 years (26,336 patient-years of follow-up); 146 individuals were diagnosed with aCRN. The model contained eight predictors, with a cross-validation median c-statistic of 0.74 and 0.75 for a 5- and 10-year prediction window, respectively. Calibration plots showed good calibration. Internal-external cross-validation results showed medium discrimination and reasonable to good calibration. The new prediction model showed good discrimination and calibration, however, generalizability results varied. Future research should focus on formal external validation and relate predicted aCRN risks to surveillance intervals prior to clinical application.
Sections du résumé
BACKGROUND & AIMS
OBJECTIVE
Colonoscopic surveillance is recommended in patients with colonic inflammatory bowel disease (IBD) given their increased risk of colorectal cancer (CRC). We aimed to develop and validate a dynamic prediction model for the occurrence of advanced colorectal neoplasia (aCRN, including high-grade dysplasia and CRC) in IBD.
METHODS
METHODS
We pooled data from six existing cohort studies from Canada, the Netherlands, the UK, and the USA. Patients with IBD and an indication for CRC surveillance were included if they underwent at least one follow-up procedure. Exclusion criteria included prior aCRN, prior colectomy, or an unclear indication for surveillance. Predictor variables were selected based on literature. A dynamic prediction model was developed using a landmarking approach based on Cox proportional hazard modelling. Model performance was assessed with Harrell's concordance-statistic (discrimination) and by calibration curves. Generalizability across surveillance cohorts was evaluated by internal-external cross-validation.
RESULTS
RESULTS
The surveillance cohorts comprised 3,731 patients, enrolled and followed-up in the time period 1973-2021, with a median follow-up of 5.7 years (26,336 patient-years of follow-up); 146 individuals were diagnosed with aCRN. The model contained eight predictors, with a cross-validation median c-statistic of 0.74 and 0.75 for a 5- and 10-year prediction window, respectively. Calibration plots showed good calibration. Internal-external cross-validation results showed medium discrimination and reasonable to good calibration.
CONCLUSION
CONCLUSIONS
The new prediction model showed good discrimination and calibration, however, generalizability results varied. Future research should focus on formal external validation and relate predicted aCRN risks to surveillance intervals prior to clinical application.
Identifiants
pubmed: 38431223
pii: S1542-3565(24)00214-3
doi: 10.1016/j.cgh.2024.02.014
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Investigateurs
Adriaan A van Bodegraven
(AA)
Herma H Fidder
(HH)
Meike M C Hirdes
(MMC)
Frank Hoentjen
(F)
Jeroen M Jansen
(JM)
Nofel Mahmmod
(N)
Andrea E van der Meulen-de Jong
(AE)
Cyriel Y Ponsioen
(CY)
Fiona D M van Schaik
(FDM)
C Janneke van der Woude
(C)
Informations de copyright
Copyright © 2024. Published by Elsevier Inc.